Brief: BGN Technologies Licenses Polymer For Targeted Cancer Therapy To Vaxil Bio
23/09/2019 12:29
Sept 23 (Reuters) - Vaxil Bio Ltd VXL.V :
* BGN TECHNOLOGIES - LICENSES POLYMER FOR TARGETED CANCER
THERAPY
TO VAXIL BIO
* BGN TECHNOLOGIES LICENSES POLYMER FOR TARGETED CANCER
THERAPY TO
VAXIL BIO
* BGN TECHNOLOGIES - ENTERED AN EXCLUSIVE WORLDWIDE LICENSE
AGREEMENT WITH VAXIL BIO FOR DEVELOPMENT AND COMMERCIALIZATION
OF TARGETED CANCER THERAPY
Source text for Eikon: ID:nPnllZKla
Further company coverage: VXL.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxil Bio
See all newsBrief: Vaxil Announces Close Of Previously Announced Non-Brokered Private Placement
Brief: Vaxil Bio Says Proposed Reverse Takeover With Green Date Terminated
Brief: Vaxil Bio Enters Into Definitive Agreement With Green Data Centers for Reverse Take Over
Brief: Vaxil Bio To Continue Actively Explore Other Strategic Options
Brief: Vaxil Bio Enters Into Letter Of Intent With Copper Bullet Mines In Respect Of A Proposed Reverse Takeover